Symptoms of Hereditary Transthyretin Amyloidosis: The Patient and Physician Perspective.
Cardiomyopathy
Diagnosis
Hereditary transthyretin amyloidosis
Patient perspective
Physician perspective
Polyneuropathy
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
17
06
2024
accepted:
09
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
This article has been co-authored by a patient living with hereditary transthyretin (ATTRv) amyloidosis and a neurologist. This rare, progressive disease is associated with impairment of multiple organ systems, including the nerves, heart, and the gastrointestinal tract, forcing patients to live with and adapt to a range of debilitating symptoms. Here, the patient and physician discuss how the symptoms of ATTRv amyloidosis profoundly impact day to day life, the difficulties with identifying the disease, and how this effects the diagnosis experience. In recent years, significant advancements have been made in the treatment and management of ATTRv amyloidosis. However, the authors highlight the urgency of increasing awareness of the disease among the wider medical community, as well as in patients who notice the symptoms, to ensure that earlier diagnosis and appropriate treatment are achieved.
Identifiants
pubmed: 39240295
doi: 10.1007/s40120-024-00657-y
pii: 10.1007/s40120-024-00657-y
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109–23.
doi: 10.2147/TCRM.S219979
pubmed: 32110029
pmcid: 7041433
Cambieri C, Libonati L, Moret F, et al. The silent period for small fiber sensory neuropathy assessment in a mixed cohort of transthyretin-mediated amyloidosis. Biomedicines. 2022;10:2073.
doi: 10.3390/biomedicines10092073
pubmed: 36140174
pmcid: 9495326
Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–78.
doi: 10.1136/jnnp-2021-327909
pubmed: 35256455
Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785–93.
doi: 10.1007/s10741-021-10080-2
pubmed: 33609196
Benson M, Dasgupta N, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag. 2020;16:749–58.
doi: 10.2147/TCRM.S185677
pubmed: 32884276
pmcid: 7434568
Bentellis I, Amarenco G, Gamé X, et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29:S65–74.
doi: 10.1007/s10286-019-00627-7
Lovley A, Raymond K, Guthrie S, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5:3.
doi: 10.1186/s41687-020-00273-y
pubmed: 33411323
pmcid: 7790957
Barroso FA, Coelho T, Dispenzieri A, et al. Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid. 2022;29(3):175–83.
doi: 10.1080/13506129.2022.2043270
pubmed: 35451899
Mallus M, Rizzello V. Treatment of amyloidosis: present and future. Eur Heart J Suppl. 2023;25:B99–103.
doi: 10.1093/eurheartjsupp/suad082
pubmed: 37091663
pmcid: 10120969
Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479–506.
doi: 10.1007/s00392-020-01799-3
pubmed: 33459839
pmcid: 8055575
Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. 2001 Nov 5 [Updated 2024 May 30]. In: GeneReviews
Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18:2286–302.
doi: 10.1007/s13311-021-01154-y
pubmed: 34850359
pmcid: 8804119
Damy T, Adam C, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29:165–74.
doi: 10.1080/13506129.2022.2035354
pubmed: 35144512
Dang D, Fournier P, Cariou E, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7:2418–30.
doi: 10.1002/ehf2.12793
pubmed: 32588554
pmcid: 7524246